Kick-starting the cancer-immunity cycle by targeting CD40
P Ellmark, SM Mangsbo, C Furebring… - …, 2015 - Taylor & Francis
P Ellmark, SM Mangsbo, C Furebring, TH Tötterman, P Norlén
Oncoimmunology, 2015•Taylor & FrancisStimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and
generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists
exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists,
they are ideal candidates for combination regimens.
generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists
exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists,
they are ideal candidates for combination regimens.
Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists, they are ideal candidates for combination regimens.
Taylor & Francis Online